Immuneering Corporation Class A Common Stock
IMRXImmuneering Corporation Class A (IMRX) is a biotechnology company focused on developing therapies for complex neurological and oncology diseases. Founded with the goal of translating computational biology and data-driven insights into innovative treatments, Immuneering leverages its proprietary platform to identify and advance novel drug candidates. The company aims to accelerate drug discovery and improve patient outcomes through its expertise in genomics, computational models, and clinical development.
Company News
U.S. stock futures declined on Thursday with investors awaiting Supreme Court ruling on tariffs and December jobs reports. AZZ surged on strong earnings, Northrop Grumman jumped on defense spending proposals, while Immuneering tumbled on disappointing trial data and Phathom dropped following stock offering announcement. Constellation Brands rose ...
Immuneering Corporation announced positive Phase 2a trial results showing 64% overall survival at 12 months for atebimetinib combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, nearly double the 35% benchmark from standard of care. The company plans to initiate its pivotal Phase 3 trial (MAPKeeper 301) in m...
Immuneering Corporation will host a conference call to discuss updated overall survival and safety data from a Phase 2a clinical trial of atebimetinib + mGnP in first-line pancreatic cancer patients, with 9 months median follow-up.
PepGen Inc. experienced a significant 112.4% pre-market stock surge after announcing an underwritten public offering of common stock and pre-funded warrants. Several other stocks showed notable pre-market movements, with some gaining and others declining.
Immuneering Corporation announced a public offering of 18,959,914 Class A common stock shares at $9.23 per share, raising approximately $175 million. Simultaneously, Sanofi will purchase 2,708,559 shares in a private placement transaction.
